HSA-Free Interferon Formulation Stabilization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current interferon-beta pharmaceutical formulations face instability issues due to denaturation and aggregation, and the use of human serum albumin (HSA) as a stabilizer poses risks of viral contamination.
Innovation Solution
Development of stabilized interferon-beta compositions without HSA, incorporating a buffer, surfactant, isotonicity agent, antioxidant, and bacteriostatic agent, specifically using Pluronic surfactants like Poloxamer 188 and methionine to enhance stability and prevent aggregation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If human serum albumin (HSA) is used as a stabilizer in interferon formulations, then protein stability is improved, but viral contamination risk increases
Solution Approach 1:
The invention removes HSA from the interferon formulation entirely, extracting the harmful component while maintaining stability through alternative excipients including surfactants, buffers, and antioxidants that do not carry viral contamination risks
Solution Approach 2:
The invention replaces the expensive and risky HSA with simpler, safer excipients that achieve the same stabilizing function without the associated viral contamination hazards
2Duration of action of stationary object
If interferon formulations are stored long-term, then therapeutic availability is improved, but protein denaturation and aggregation increase
Solution Approach 1:
The formulation includes excipients such as surfactants and antioxidants that are added beforehand to prevent denaturation and aggregation during storage, addressing stability issues before they occur rather than treating them after
Solution Approach 2:
The invention optimizes pH, ionic strength, and excipient concentrations to create a formulation environment that maintains interferon stability throughout the intended storage period, allowing long-term availability without degradation
3Stability of the object's composition
If interferon formulations contain multiple excipients for stability, then protein protection is improved, but formulation complexity increases
Solution Approach 1:
The formulation uses excipients that perform multiple functions simultaneously - for example, buffers that maintain pH while also providing ionic strength for stability, or surfactants that prevent aggregation while also solubilizing the protein
Solution Approach 2:
The invention combines multiple stabilizing functions into a coordinated excipient system where buffers, surfactants, and antioxidants work together synergistically to protect the interferon through various degradation pathways
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The HSA-free formulations maintain at least 60% biological activity over 12-24 months, offering improved stability and safety by reducing viral transmission risks while preventing protein aggregation and oxidation.
Implementation Method 1
The HSA-free formulations maintain at least 60% biological activity over 12-24 months, offering improved stability and safety by reducing viral transmission risks while preventing protein aggregation and oxidation.
Implementation Method 2
Development of stabilized interferon-beta compositions without HSA, incorporating a buffer, surfactant, isotonicity agent, antioxidant, and bacteriostatic agent, specifically using Pluronic surfactants like Poloxamer 188 and methionine to enhance stability and prevent aggregation.
Data Source
AI summary
A stabilized HSA-free liquid pharmaceutical composition is described, which comprises an interferon (IFN), wherein said formulation is a solution that comprises a buffer, a surfactant, an isotonicity agent and an antioxidant. Preferably the interferon is human recombinant IFN-beta.